Mr Sebastien Ouchouche, Principal Engineer
Europe 2017 Presentation - Galvani Bioelectronics*
Europe 2017 Audio Presentation - Galvani Bioelectronics*
If you already have access, please [Login]
Access can be purchased via IDTechEx Credits
Galvani Bioelectronics is the joint venture between one of the world's largest pharmaceuticals (GlaxoSmithKline) and one of the world's largest electronics company (Alphabet). In this presentation Ouchouche will cover how they are tackling the huge healthcare needs facing the population of the world.
講演者の経歴 (Sebastien Ouchouche)
Sebastien leads the mechanical design efforts for the neural interface development at Galvani Bioelectronics.
Prior to his work at Galvani Bioelectronics, Sebastien worked in many areas of design engineering, across several countries. These include piezoelectric micro-systems in NOLIAC (Denmark) and Safran Electronics & Defense (France), before moving to implantable medical devices when he joined Sorin/LivaNova (France) to develop pacemaker and defibrillator systems, with specific focus on the leads and interfaces. Sebastien also spent 4 years at Medtronic (Netherlands) to work on the development of thin-film based leads and interfaces for deep brain stimulation.
Sebastien has a Master of Science in Mechanical and Microtechnoloy Engineering from the French National School of Mechanical Engineering and Microtechnology (ENSMM).
会社紹介 (Galvani Bioelectronics)
View Galvani Bioelectronics Timeline
Formed through a partnership between global healthcare company, GSK, and leading technology company, Verily Life Sciences, Galvani Bioelectronics combines the complementary expertise of its parent companies to enable the research, development and commercialisation of bioelectronic therapies.
Bioelectronic medicine is an emerging scientific field, aiming to use tiny implantable devices to change precise electrical signals in nerves to treat a range of debilitating chronic diseases. Galvani Bioelectronics represents an important step change in the research and development of these medicines, combining GSK's discovery and development expertise and deep understanding of disease biology with Verily's world leading expertise in the miniaturisation of low power electronics, device development, data analytics and software development for clinical applications.